Adropin inhibits fibrosis in SSc

IF 29.4 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2024-05-03 DOI:10.1038/s41584-024-01121-9

Robert Phillips

引用次数: 0

Abstract

The peptide hormone adropin, which is downregulated in dermal fibroblasts in patients with systemic sclerosis (SSc), inhibits TGFβ-mediated fibrosis in in vitro and ex vivo models of human skin, and has potential for the treatment of SSc.

查看原文本刊更多论文

阿托品能抑制 SSc 的纤维化

在系统性硬化症（SSc）患者的真皮成纤维细胞中下调的肽类激素阿托品，在体外和体外人体皮肤模型中可抑制 TGFβ介导的纤维化，具有治疗系统性硬化症的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.